無料セミナー : 2020年3月4日『Future of Immuno-Oncology 免疫腫瘍学の未来』 DelveInsight Business Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

重症筋無力症(MG) - 市場の洞察、疫学、市場予測

Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 703502
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
重症筋無力症(MG) - 市場の洞察、疫学、市場予測 Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast - 2028
出版日: 2019年01月01日 ページ情報: 英文 100 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の重症筋無力症(MG)の2016年の総有病数は12万9,267人、市場規模は29億9,810万米ドルと推計されています。

当レポートでは、主要7カ国の重症筋無力症(MG)市場を調査し、疾患の概要、患者背景、主要7カ国における重症筋無力症の有病数・診断数の予測(今後10年間分)、診断ガイドライン、上市薬および新薬の概要、市場の成長要因と障壁、競合情勢などを包括的にまとめています。

目次

第1章 重要洞察

第2章 重症筋無力症市場の概要

第3章 市場シェア(最新値)

第4章 市場シェア(予測値)

第5章 疾患概要:重症筋無力症(MG)

  • イントロダクション
  • 重症筋無力症の種類
  • 重症筋無力症の分類
  • 病因
  • 遺伝的概要
  • 危険因子
  • 兆候と症状
  • 病態生理
  • 併存疾患
  • 診断

第6章 疫学と患者人口

  • 主な所見
  • 人口と予測パラメーター
  • 主要7カ国の総有病数
  • 重症筋無力症の疫学:国別
    • 米国
      • 前提と根拠
      • 重症筋無力症の総有病数
      • 重症筋無力症の総有病数:性別
      • 重症筋無力症の診断数
      • 重症筋無力症の診断数:重症度別
      • 重症筋無力症の診断数:自己抗体別
    • ドイツ
      • 重症筋無力症の総有病数
      • 重症筋無力症の総有病数:性別
      • 重症筋無力症の診断数
      • 重症筋無力症の診断数:重症度別
      • 重症筋無力症の診断数:自己抗体別
    • フランス
      • 重症筋無力症の総有病数
      • 重症筋無力症の総有病数:性別
      • 重症筋無力症の診断数
      • 重症筋無力症の診断数:重症度別
      • 重症筋無力症の診断数:自己抗体別
    • イタリア
      • 重症筋無力症の総有病数
      • 重症筋無力症の総有病数:性別
      • 重症筋無力症の診断数
      • 重症筋無力症の診断数:重症度別
      • 重症筋無力症の診断数:自己抗体別
    • スペイン
      • 重症筋無力症の総有病数
      • 重症筋無力症の総有病数:性別
      • 重症筋無力症の診断数
      • 重症筋無力症の診断数:重症度別
      • 重症筋無力症の診断数:自己抗体別
    • 英国
      • 重症筋無力症の総有病数
      • 重症筋無力症の総有病数:性別
      • 重症筋無力症の診断数
      • 重症筋無力症の診断数:重症度別
      • 重症筋無力症の診断数:自己抗体別
    • 日本
      • 重症筋無力症の総有病数
      • 重症筋無力症の総有病数:性別
      • 重症筋無力症の診断数
      • 重症筋無力症の診断数:重症度別
      • 重症筋無力症の診断数:自己抗体別

第7章 現在の治療法

  • 重症筋無力症の管理に関する国際コンセンサスガイダンス
  • 重症筋無力症に対する日本の臨床ガイドライン

第8章 アンメットニーズ

第9章 上市薬

  • キークロスコンペティション
  • ソリリス:Alexion Pharmaceuticals
    • 医薬品の概要
    • 規制のマイルストーン
    • 利点と欠点
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • Mestinon:Valeant Pharmaceuticals
  • プログラフ:アステラス製薬
  • ヴェノグロブリンIH:田辺三菱製薬

第10章 新薬

  • キークロスコンペティション
  • 第III相試験
  • Firdapse:Catalyst Pharmaceuticals
    • 医薬品の概要
    • 開発活動
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • Hizentra:CSL Behring
  • IGIV-C:Grifols Therapeutics
  • 第II相試験
  • Rozanolixizumab: UCB Pharma
  • CFZ533: Novartis
  • Efgartigimod : Argenx
  • RA101495: Ra Pharmaceuticals

第11章 重症筋無力症:主要7カ国市場の分析

  • 主な所見
  • 主要7カ国における重症筋無力症の市場規模

第12章 市場展望:国別

  • 米国:市場の見通し
    • 市場規模
    • 重症筋無力症の市場規模
    • 市場規模:上市薬別
    • 市場規模:新薬別
  • EU5カ国:市場の見通し
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本:市場見通し

第13章 市場の成長要因

第14章 市場の障壁

第15章 付録

第16章 報告方法

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 7: Treatable Cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 12: Treatable Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Myasthenia Gravis in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Myasthenia Gravis in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Myasthenia Gravis in France (2016-2028)
  • Table 16: Diagnosed Cases of the Myasthenia Gravis in France (2016-2028)
  • Table 17: Treatable Cases of the Myasthenia Gravis in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 22: Treatable Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 27: Treatable Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 32: Treatable Cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Myasthenia Gravis in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Table 37: Treatable Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Table 42:7MM- Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Table 45: United States-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Table 48: Germany-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Table 51: France-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Table 54: Italy-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Table 57: Spain-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Table 60:UK-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Table 63: Japan-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 7: Treatable Cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 17: Treatable Cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 32: Treatable Cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Myasthenia Gravis in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Figure 45: United States-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Figure 51: France-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Figure 60:UK-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Myasthenia Gravis in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Myasthenia Gravis by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Myasthenia Gravis by Therapies in USD MM (2016-2028)
目次
Product Code: DIMI0140

DelveInsight's "Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Myasthenia Gravis epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Myasthenia Gravis Understanding and Treatment Algorithm

The market report provides the overview of the Myasthenia Gravis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Myasthenia Gravis Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Myasthenia Gravis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Myasthenia Gravis Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Myasthenia Gravis Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Myasthenia Gravis market.

Myasthenia Gravis Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Myasthenia Gravis Report Insights

  • Patient Population in Myasthenia Gravis
  • Therapeutic Approaches in Myasthenia Gravis
  • Myasthenia Gravis Pipeline Analysis
  • Myasthenia Gravis Market Size and Trends
  • Myasthenia Gravis Market Opportunities
  • Impact of upcoming Therapies in Myasthenia Gravis

Myasthenia Gravis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Myasthenia Gravis Report Assessment

  • Current Treatment Practices in Myasthenia Gravis
  • Unmet Needs in Myasthenia Gravis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Myasthenia Gravis market
  • Organize sales and marketing efforts by identifying the best opportunities for Myasthenia Gravis market
  • To understand the future market competition in the Myasthenia Gravis market.

Table of Contents

1. Report Introduction

2. Myasthenia Gravis Market Overview at a Glance

  • 2.1. Market Share Distribution of Myasthenia Gravis in 2016
  • 2.2. Market Share Distribution of Myasthenia Gravis in 2028

3. Disease Background and Overview: Myasthenia Gravis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Myasthenia Gravis in 7MM
  • 4.3. Total Prevalent Patient Population of Myasthenia Gravis in 7MM - By Countries

5. Epidemiology of Myasthenia Gravis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.1.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.1.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.1.5. Diagnosed Cases of the Myasthenia Gravis
    • 5.1.6. Treatable Cases of the Myasthenia Gravis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.4.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.4.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.4.5. Diagnosed Cases of the Myasthenia Gravis
    • 5.4.6. Treatable Cases of the Myasthenia Gravis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.5.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.5.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.5.5. Diagnosed Cases of the Myasthenia Gravis
    • 5.5.6. Treatable Cases of the Myasthenia Gravis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.6.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.6.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.6.5. Diagnosed Cases of the Myasthenia Gravis
    • 5.6.6. Treatable Cases of the Myasthenia Gravis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.7.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.7.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.7.5. Diagnosed Cases of the Myasthenia Gravis
    • 5.7.6. Treatable Cases of the Myasthenia Gravis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.8.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.8.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.8.5. Diagnosed Cases of the Myasthenia Gravis
    • 5.8.6. Treatable Cases of the Myasthenia Gravis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.9.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.9.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.9.5. Diagnosed Cases of the Myasthenia Gravis
    • 5.9.6. Treatable Cases of the Myasthenia Gravis

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Myasthenia Gravis

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Myasthenia Gravis

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Myasthenia Gravis : 7MM Market Analysis

  • 12.1. 7MM Market Size of Myasthenia Gravis
  • 12.2. 7MM Percentage Share of drugs marketed for Myasthenia Gravis
  • 12.3. 7MM Market Sales of Myasthenia Gravis by Products

13. Myasthenia Gravis : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Myasthenia Gravis in United States
    • 13.1.2. Percentage Share of drugs marketed for Myasthenia Gravis in United States
    • 13.1.3. Market Sales of Myasthenia Gravis by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Myasthenia Gravis in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Myasthenia Gravis in Germany
      • 13.2.1.3. Market Sales of Myasthenia Gravis by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Myasthenia Gravis in France
      • 13.2.2.2. Percentage Share of drugs marketed for Myasthenia Gravis in France
      • 13.2.2.3. Market Sales of Myasthenia Gravis by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Myasthenia Gravis in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Myasthenia Gravis in Italy
      • 13.2.3.3. Market Sales of Myasthenia Gravis by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Myasthenia Gravis in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Myasthenia Gravis in Spain
      • 13.2.4.3. Market Sales of Myasthenia Gravis by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Myasthenia Gravis in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Myasthenia Gravis in United Kingdom
      • 13.2.5.3. Market Sales of Myasthenia Gravis by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Myasthenia Gravis in Japan
    • 13.3.2. Percentage Share of drugs marketed for Myasthenia Gravis in Japan
    • 13.3.3. Market Sales of Myasthenia Gravis by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

Back to Top